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Rat M3 mAChR subtype was stably expressed in RAT 1 cells. Investigation of the pharmacological and biochemical 
properties of the cloned M3 receptors revealed that they mediate phosphoinositide hydrolysis but not adenylate cyclase 
inhibition. The similarities and differences between the properties of cloned rat Ml and M3 receptors are discussed. 
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1. INTRODUCTION 
Muscarinic acetylcholine receptors (mAChR) 
are a family of at least four distinct but highly 
homologous subtypes, coded for by four different 
genes and termed Ml, M2, M3 and M4 ([ 1,2] and 
references therein). The binding of agonist to 
mAChR elicits multiple biochemical responses via 
activation of G proteins, such as inhibition of 
adenylate cyclase (AC), induction of phosphoino- 
sitide (PI) hydrolysis, and opening of potassium, 
calcium and sodium channels (reviews [3,4]). 
It seems reasonable to assume that individual 
muscarinic receptor subtypes might display 
characteristic ligand-binding profiles as well as 
specific coupling to the various second-messenger 
signaling systems mediated by mAChR. However, 
correlation between a specific subtype and a par- 
ticular second-messenger system(s) is difficult to 
demonstrate, partly because of the lack of a 
homogeneous ource for each of the four subtypes. 
In order to determine the pharmacological and 
biochemical effects of a particular subtype and to 
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compare them with those of others, each subtype 
must first be expressed separately in the same 
cellular context. Recently we isolated the rat Ml 
and M3 receptor genes and stably expressed the Ml 
subtype in a rat cell line lacking endogenous 
mAChR. The cloned Ml receptors were found to 
mediate both AC inhibition and PI turnover [5]. 
Since the Ml and M3 subtypes show greater 
homology to one another than to either M2 or M4 
[I], it was of particular interest to determine and 
compare their ligand-binding profiles and 
biochemical responses. In the present study we 
stably expressed rat M3 mAChR subtype in the 
same rat cell line as that used earlier for the expres- 
sion of Ml receptors. We describe here the phar- 
macological and biochemical properties of the 
cloned M3 receptor. 
2. MATERIALS AND METHODS 
2.1. Materials 
A’-[‘HlMethylscopolamine ([3H]NMS) (73 Ci/mmol) and 
(3H]quinuclidinyl benzilate ([sH]QNB) (43.6 Ci/mmol) were 
purchased from NEN. Pirenzepine hydrochloride (PZ) and AF- 
DX 116 were donated by Karl Thomae (FRG), and 
4-diphenylacetyl-N-methylpiperidine methiodide (4-DAMP) 
was a gift from Dr R. Barlow. Atropine sulfate, car- 
bamylcholine and oxotremorine were from Sigma. 
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2.2. Expression of rat h43 receptors 
M3 genomic AccI-NdeI fragment was end-filled and sub- 
cloned into the end-filled EcoRI site of the mammalian expres- 
sion vector pMV7 [6] (gift from Dr B. Weinstein). RAT-l cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal calf serum. Cells were plated in 
IO-cm Petri dishes (5 x 10’ cells per dish) and transfected with 
2 pg of pMV7-M3 vector by calcium phosphate precipitation 
[7]. Colonies were selected and grown in medium containing the 
antibiotic G418 (350 #g/ml). 
2.3. L&and-binding assay 
Cells were scraped from the plates with phosphate-buffered 
saline (PBS), pH 7.4, and homogenates were prepared as 
described [5]. As also described [8], the binding of labeled 
muscarinic antagonists to homogenates of cell cultures was 
assayed by the filtration method [5,8], the binding of unlabeled 
muscarinic agonists was measured by competition with 1.8 nM 
[3H]4NMPB [5,8], and binding isotherms and competition 
curves were analyzed by a nonlinear curve-fitting procedure us- 
ing a model for either one or two binding sites [5,8]. 
2.4. Assay for phosphoinositide hydrolysis 
Cells were labeled with 5 &i/ml [3H]inositol (17 Ci/mmol; 
Amersham) for 18 h, washed 3 times with PBS and incubated 
for 10 min with DMEM containing 8 mM CaClz, 20 mM Hepes 
buffer and 10 mM LiCl [5,9]. Different concentrations of car- 
bachol were added for an additional 30 min. The reaction was 
terminated by resuspension of the cells in Hz0 and the addition 
of chloroform/methanol (1:2). The water-soluble products of 
PI hydrolysis were separated by extraction of the aqueous phase 
from the chloroform phase followed by ion-exchange 
chromatography. 
2.5. Inhibition of CAMP accumulation 
Cells were incubated with DMEM medium containing 20 mM 
Hepes and 2OOpM isobutylmethylxanthine for 20 min, fol- 
lowed by incubation with 1 gM isoproterenol for 1 min with 
different concentrations of carbachol. The reaction was then 
terminated by the addition of 50 mM hot (SO’C) acetate buffer 
(pH 4) to the cells. The level of CAMP was determined as 
described [5]. 
3. RESULTS 
3.1. Expression of rat M3 receptor subtype in 
RA T-I cells 
Rat M3 gene, referred to here as M3 [l], was 
isolated as described [5]. Since the protein-coding 
region of M3 is contained within a single exon [l], 
genomic clone was used to isolate a 3.8-kb genomic 
AccI-NdeI fragment which contains the entire 
coding sequence for M3 mAChR and the 
polyadenylation signal. This fragment was 
subcloned into the EcoRI site of the mammalian 
expression vector pMV7, thus generating the 
muscarinic receptor construct pMV7-M3. RAT-l 
cells were transfected with the muscarinic expres- 
sion vector pMV7-M3, following the selection of 
stable transformants by employing the antibiotic 
G418. Colonies resistant o G418 were isolated and 
checked for the expression of M3 mRNA (not 
shown) and for binding of the muscarinic an- 
tagonist t3H]4NMPB to their membranes. One of 
the colonies, M3-2, which was found to express 
[3H]4NMPB binding sites at a level (110 fmol/mg 
protein) comparable to that of PRR-1 (cloned Ml 
receptor in the same cell line [5]), was selected for 
further analysis. 
3.2. Binding characteristics 
Membranes prepared from M3-2 cells were ex- 
amined for the binding of muscarinic antagonists 
and agonists. The antagonists [3H]4NMPB, 
[3H]QNB and [3H]NMS yielded saturable binding 
curves (not shown) with the following binding 
parameters: for [3H]4NMPB, Bma, = 110 fmol/mg 
protein, Ko = 1.6 nM; for [3H]QNB, B,,, = 
120 fmol/mg protein, KD = 1.3 nM; for 
[3H]NMS, B,,, = 54 fmol/mg protein, KD = 
0.54 nM. Competition for [3H]4NMPB labeled 
sites by the selective muscarinic antagonist 
4-DAMP, PZ and AF-DX 116 is illustrated in 
fig. 1. Analysis of these curves (table 1) yielded two 
binding states of the M3 receptor, one of high and 
one of low affinity, for both 4-DAMP and PZ. For 
AF-DX 116, however, the analysis showed a single 
low-affinity binding state of the receptor with a KD 
of 4pM (m = 1.1). 
The binding properties of the muscarinic 
agonists carbamylcholine, oxotremorine and 
acetylcholine were examined by competition with 
3H-antagonist. All three agonists showed both 
high- and low-affinity binding for [3H]4NMPB- 
labeled sites (table 1). When Gpp(NH)p (300 PM) 
was included in the incubation mixture the car- 
bamylcholine binding curve was shifted to the right 
(not shown), and analysis revealed that 57% of the 
high-affinity binding sites had been converted to 
the low-affinity state. 
3.3. Mediation of phosphoinositide hydrolysis by 
cloned M3 receptors 
PI hydrolysis was determined by measuring the 
accumulation of [3H]inositol trisphosphate 
([3H]IP3), [3H]inositol bisphosphate ([3H]IPz) and 
[3H]inositol monophosphate ([3H]IPi) in the 
presence of 10 mM LiCl (which blocks IPi [lo]). 
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Fig. 1. Concentration-dependent displacement of [-‘H]4NMPB (1.8 nM) by the selective muscarinic antagonists 4-DAMP, pirenzepine 
and AF-DX 116. Binding assays were performed as described in section 2 in homogenates prepared from M3-2 cells. 
Treatment of cells with the muscarinic agonist car- 
bamylcholine (10m3 M), for various periods re- 
vealed time-dependent accumulation of IP 1, IPz, 
IP3; for example, incubation for 10 min increased 
their accumulation by 1.8-, 1.5 and 1.5fold, 
respectively, while incubation for 30 min increased 
it by 3.6-, 3.3- and l.Sfold, respectively. Accor- 
dingly, in subsequent experiments a 30 min period 
of incubation with carbamylcholine was adopted 
in order to allow maximal accumulation of [3H]IPi 
as an index of PI hydrolysis. The concentration 
dependence of the carbamylcholine effect on PI 
hydrolysis is illustrated in fig.2. As shown, the 
EDso of carbamylcholine-stimulated PI hydrolysis 
was 7 x 10-s M. Maximum hydrolysis of 3.6-fold 
relative to the basal value was reached at 10m3 M 
Table 1 
Parameters obtained from displacement of i3H]4NMPB 
(1.8 nM) by antagonists and agonists in homogenates of M3-2 
cells 
Ligands Ku KL RH nH 
4-DAMP 1.3 nM 116 nM 83% 0.7 
Pirenzepine 76 nM 6.2 FM 49% 0.5 
Acetylcholine 3.9pM 57 pM 54% 0.5 
Oxotremorine 8.3pM 47 pM 46% 0.7 
Carbamylcholine 74 PM l.lmM 56% 0.8 
Values are means of three experiments. RH is the percentage of 
high-affinity binding sites. KH and KL are the dissociation 
constants for the binding of ligands to the high- and low- 
affinity sites, respectively. Values were determined by 
Scatchard analysis and nonlinear least-squares best-fit 
computer analysis 
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carbamylcholine. This carbamylcholine effect was 
completely blocked by 50 PM atropine, but was 
unaffected by pretreatment with pertussis toxin 
(100 ng/ml). 
3.4. Testing for inhibition of adenylate cyclase in 
M3-2 cells by cloned A43 receptors 
Examination of the effects of various concentra- 
tions (10-10-10-3 M) of carbamylcholine on 
isoproterenol-induced CAMP levels revealed no 
significant reduction in CAMP levels over this con- 
centration range. Thus, in control M3-2 cells 
-log [ Carbamylcholine lb) 
Fig.2. Concentration dependence of the carbamylcholine effect 
on PI hydrolysis in M3-2 cells. Cells were incubated with the 
indicated concentrations of carbamylcholine for 30 min at 
37°C. [3H]IPI was determined as described in section 2. The 
data points represent the percentages of maximal response in 
the presence of carbamylcholine. 
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(without carbamylcholine) the level of isoprotere- 
nol-induced CAMP was 26.6 f 5.9 pmol/106 cells, 
whereas jn c&s trea& for 1 mm w>$n 1%’ M 0~ 
10e6 M carbamylcholine the CAMP levels were 
20.4 & 4.2 and 26.9 & 6.0 pmol/106 cells, respec- 
tively. It should be noted that in some experiments 
carbamylcholine at 10e3 M increased isoprote- 
renol-induced CAMP levels by 2550% above the 
control. 
4. DISCUSSION 
Our data demonstrate that cloned M3 receptors 
from M3-2 cells (RAT-l cells stably transfected 
with M3 muscarinic expression vector) bind 
muscarinic antagonist and agonist, couple to G- 
protein and mediate PI turnover but not AC in- 
hibition. M3-2 cells were found to express 1.4 x 
lo4 M3 receptors per cell. This receptor number is 
close to that observed for cell lines expressing en- 
dogenous muscarinic receptors (IS] and references 
therein) as well as for PRR-1 (RAT-l cells in which 
cloned rat MI ~ecqKs5~55 are stbly exgrp,ssd a< 2 x 
lo4 receptors per cell). One may thus reliably com- 
pare the binding profiles and biochemical 
responses of cloned M3 receptors with those of en- 
dogenous receptors and of cloned rat Ml 
recercars. 
The demonstratjon of multiple muscarinjc 
receptor subtypes suggests the possible existence of 
a mechanism by which a single ACh 
neurotransmitter can elicit distinct cellular 
respconses, ‘I.e. b_v Ihe coufim> 05 inbi\;lhu& recep- 
tor subtypes to different G proteins and/or dif- 
fererf sjgnalingsysfems. A comparison of our data 
concerning the biochemical responses of cloned 
Ml and M3, when expressed within the same 
cellular context, indicates that this may indeed be 
the case. Thus, as we reported recently [S], rat Ml 
receptors mediate both PI hydrolysis and AC in- 
hibition, while rat M3 receptors mediate PI 
hydrolysis only. In addition, human cloned M2 is 
reportedly coupled to both AC inhibition and PI 
turnover [ 111. 
In cloned rat Ml receptors the inhibition of 
CAMP accumulation was atropine blocked and 
dose dependent ( 10e9- 1O-6 M carbamylcholine), 
with a maximum effect at about 10m6 M car- 
bamylcholine. At higher agonist concentration 
however, we observed in both rat Ml and M3 
receptor subtypes an increased accumulation of 
CAMP (see also below), which was blockable by 
J &5 atropjne. 
Although Ml and M3 receptors differ in their 
response to AC inhibition, both of them mediate 
PI hydrolysis with similar EDso values. Their dif- 
ference in maximal response (3.3-fold for M3 in 
M3-2 cells versus 7.5fold for Ml in PRRl cells [5]) 
can be explained by the 30% larger receptor 
number observed for Ml in PRRl cells than for 
M3 in M3-2 cells, Previous studies on cloned 
muscarinic receptors [2,1 l] have already 
demonstrated that the maximal effect of PI 
hydrolysis may depend on the receptor number. A 
comparison of the binding profiles of Ml and M3 
receptors reveals similarities in their binding af- 
finities for the selective muscarinic antagonists AF- 
DX 116, PZ and 4-DAMP; this finding is conds- 
tent with the assignment of cloned M3 receptors to 
the Ml class [l]. However, agonist binding af- 
finities are about IO-fold higher fur Ml than for 
M3 cloned receptors. 
%We <KS pq% w?&s in pq3%&&n, Pe%?& et 
al. [2] reported that cloned human M3 and Ml 
receptors in human embryonic kidney cells mediate 
PI hydrolysis but not AC inhibition. Their results 
are in agreement with ours with regard to the rat 
&4J recegtar but differ Ear the MI cecepcar, where 
inhibition of CAMP accumulation was observed in 
addition to PI hydrolysis. This apparent discrepan- 
cy between our findings and those reported for 
human Ml may result from one or more of the 
‘I &>owjnz. $1) TifCieT ences in pIDpeti&s d the cell 
lines used for the expression of the Ml receptors. 
{ii) Difference in receptor number: e.g. ,. 14.1 x 304 
[3H]QNB sites per cell in HMl cells versus 2 x lo4 
[3H]QNB sites per cell in PRRl cells. (iii) In HMl 
carbamylcholine concentrations higher than 
10m6 M lead to a muscarinically mediated increase 
in CAMP accumulation, rather than a reduction in 
CAMP levels, as also observed for rat Ml recep- 
tors. However, in contrast to the maximal increase 
of 9.8-fold in CAMP accumulation reported for 
HMl, we observed a maximal increase of only 
2-fold in the PRR-1 cells; thus, perhaps the large 
increase in CAMP level on the one hand masks the 
effect of CAMP reduction on the other. The nature 
of this CAMP-muscarinic mediated increase in 
both types of mAChR subtypes is currently under 
investigation in our laboratory. 
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